Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Medical Care Announces Closing of the

License Agreement for Intravenous Iron Products

Germany Fresenius Medical Care AG & Co. KGaA, the world s

largest provider of dialysis products and services, today announced the closing of an exclusive

license agreement with Luitpold Pharmaceuticals, Inc., and its subsidiary

American Regent, Inc. for the manufacture and distribution of intravenous

(I.V.) iron products in the USA.

follows completion of the US Federal Trade Commission s (FTC) review of the

license agreement under the Hart-Scott-Rodino Act and the issuance of a consent

order to permit the closing.

Fresenius Medical Care entered into a separate and independent license and

distribution agreement with Galenica Ltd. and its subsidiary Vifor Pharma, for

certain countries in Europe and the Middle East, to market and distribute

intravenous Iron products, such as Venofer and Ferinject for dialysis treatment.

license agreement among Fresenius USA Manufacturing, Inc. (FUSA), Luitpold

Pharmaceuticals Inc., and American Regent, Inc. provides FUSA with exclusive

rights to manufacture and distribute Venofer to freestanding (non-hospital

based) US dialysis facilities. Luitpold Pharmaceuticals will continue to sell Venofer

for use in treating chronic kidney disease patients not yet on dialysis and in

treating patients with renal failure in hospitals.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented:

are pleased to be able to complete this agreement which strengthens our ability

to improve the treatment of Iron Deficiency Anemia experienced by dialysis

patients. We are delighted to have Galenica Ltd., Vifor Pharma, Luitpold

Pharmaceuticals, Inc. and American Regent, Inc., as partners. The license to make and

distribute these products is an important milestone in the execution of Fresenius

Medical Care s renal pharma strategy.

Fresenius Medical Care is the world s largest integrated provider of

products and services for individuals undergoing dialysis because of chronic

kidney failure, a condition that affects more than 1,600,000 individuals

worldwide. Through its network of 2,318 dialysis clinics in North America,

Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides

dialysis treatment to more than 180,000 patients around the globe (as of June 30,

2008). Fresenius Medical Care is also the world s leading provider of dialysis

products such as hemodialysis machines, dialyzers and related disposable

products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange

(FME, FME3) and the New York Stock Exchange (FMS, FMS/P). For more information

about Fresenius Medical Care visit the Company s website at www.fmc-ag.com.

diversified group active throughout the healthcare market which, among other

things, develops, manufactures and commercialises pharmaceutical products, runs

pharmacies, provides logistical and database services and sets up networks. The

Galenica Group enjoys a leading position in all its business sectors Pharma,

Logistics, HealthCare Information and Retail. A large part of the Group s

income is generated by international operations. Additional information on the

Galenica Group can be found at www.galenica.com.

Luitpold Pharmaceuticals, Inc., headquartered in Shirley, NY,

manufactures and distributes over 65 pharmaceutical products including Venofer (iron sucrose injection, USP), the leading IV

iron therapy in the U.S., through its human health subsidiary, American Regent,

Inc. Luitpold Pharmaceuticals, Inc., a Daiichi-Sankyo Group company, also

markets dental bone regeneration products and veterinary pharmaceuticals

through its Osteohealth and Animal Health divisions. Daiichi Sankyo Company,

Ltd., established in 2005 after the merger of two leading century-old Japanese

pharmaceutical companies, is a global pharmaceutical innovator, continuously

generating innovative drugs that enrich the quality of life for patients around

the world. For more information about Luitpold see www.luitpold.com.

This release contains forward-looking

statements that are subject to various risks and uncertainties. Actual results

could differ materially from those described in these forward-looking

statements due to certain factors, including changes in business, economic and

competitive conditions, regulatory reforms, foreign exchange rate fluctuations,

uncertainties in litigation or investigative proceedings, and the availability

of financing. These and other risks and uncertainties are detailed in Fresenius

Medical Care AG & Co. KGaA s reports filed with the U.S. Securities and

Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not

undertake any responsibility to update the forward-looking statements in this